Remiges Ventures
VC Fund
Cambridge, United States
Remiges Ventures is a venture capital firm that focuses on groups and businesses in the Japanese academia and pharmaceutical industry.
- Total investments:
- 25
- Last investment:
- Lead investor:
- 64%
- Fund size:
- $95M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Remiges Ventures invests in
Stages Remiges Ventures invests in
Countries Remiges Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $2.6M–$10M
- Series A
- $6.8M–$25M
- Series B
- $8.2M–$41M
Investment Focus
Industry
- Biotechnology 12 (48%)
- Medical 6 (24%)
- Health Care 5 (20%)
- Therapeutics 5 (20%)
- Life Science 3 (12%)
Stage
- Series A 10 (40%)
- Series B 6 (24%)
- Seed 3 (12%)
- Series C 2 (8%)
Country
- United States 7 (28%)
- Japan 2 (8%)
- Canada 1 (4%)
- France 1 (4%)
- Israel 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Taro Inaba
Founder and Managing Partner
|
Founder and Managing Partner | Total investments: 4 | Find email | |
Takahide Koda
Partner
|
Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Restore Vision is a biotechnology company developing a visual restoration gene therapy for retinitis pigmentosa. Restore Vision develops eye disease therapeutic agents. | $8.2M / Series B / Apr 15, 2026 | ||
Kupando
|
Kupando is a biopharmaceutical company that develops agonists to stimulates innate immunity. | $11.5M / Series A / Mar 18, 2026 | |
| Glycomine is early-stage biotech working on replacement therapies for rare diseases. There are approximately 7,000 rare disorders worldwide. Each day more are being discovered. 95% of rare diseases have not one single FDA-approved treatment. Glycomine develops therapeutics for diseases that have no treatment options. | $115M / Series C / Apr 16, 2025 | ||
| KisoJi Biotechnology is a biotechnology company focused on healthcare and life sciences for research and development industries. | $40.6M / Series B / Dec 02, 2024 | ||
| Immunis a private biotechnology company developing a novel treatment for age and disease-related immune decline. | $25M / Series A / Jul 01, 2024 | ||
| Cyrano Therapeutics is developing an intranasal product designed to restore function in patients with a chronic loss of taste and smell. The company's product (CYR-001) repurposes an approved molecule (Theophylline) for this new indication and has been tested with success in a pilot study. Eight out of the 10 patients treated had significantimprovement in taste and smell within 2 weeks with no reported side effects. The primary treatment provider will be the Otolaryngologist (Ear, Nose, and Throat specialist) and credible clinical investigators in this specialty have been identified and have expressed interest in participating in the clinical program.Cyrano Therapeutics was founded in 2014 and is headquartered in Washington, DC, USA. | $9M / Series B / Jan 16, 2024 | ||
| Restore Vision is a biotechnology company developing a visual restoration gene therapy for retinitis pigmentosa. Restore Vision develops eye disease therapeutic agents. | $4.2M / Series A / Dec 15, 2023 | ||
| Restore Vision is a biotechnology company developing a visual restoration gene therapy for retinitis pigmentosa. Restore Vision develops eye disease therapeutic agents. | $9.1M / Series A / Jun 05, 2023 | ||
|
Kupando
|
Kupando is a biopharmaceutical company that develops agonists to stimulates innate immunity. | $12.5M / Series A / Sep 26, 2022 | |
| Immunis a private biotechnology company developing a novel treatment for age and disease-related immune decline. | $10M / Series A / Aug 03, 2022 | ||
| See all 25 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Remiges Ventures invest in?
Remiges Ventures invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 25 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Remiges Ventures's check size?
Remiges Ventures typically joins rounds of $2.6M–$10M at Seed, $6.8M–$25M at Series A and $8.2M–$41M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Remiges Ventures participates in.
How do I contact Remiges Ventures?
Public channels for Remiges Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Remiges Ventures?
The team at Remiges Ventures includes Taro Inaba (Founder and Managing Partner) and Takahide Koda (Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
